Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence?
Scaling-up opiate substitution therapy and high coverage needle and syringe programmes can reduce hepatitis C prevalence among injecting drug users, but reductions can be modest and require long-term sustained intervention coverage. In high coverage settings, other interventions are needed to further decrease hepatitis C prevalence. In low coverage settings, sustained scale-up of both interventions is needed.
Tumor invasion of the soft tissue beyond hilar region would not be a prognostic factor in patients who have undergone curative resection for primary lung cancer, although investigation of larger number of cases will be needed to confirm the validity of our conclusion.